Drug Challenge Procedure Note

Procedure: Drug Challenge - Graded

Medication Challenged: [Generic name, formulation, concentration]

Route: [oral / IV / IM / subcutaneous / other]

Date and Location: [Date; location/unit]

Performing Clinician: [Name, credentials]

Start Time: [HH:MM]

End Time: [HH:MM]

Observation End Time: [HH:MM]

Emergency Readiness: [Confirmation of appropriate clinical setting, trained staff, continuous monitoring, and availability of epinephrine, airway equipment, IV supplies, and rescue medications]

Indication / Clinical Question

[Indication for graded drug challenge] (State why the drug is needed or why delabeling is pursued, such as optimizing therapy, perioperative prophylaxis, or avoiding unnecessary broad-spectrum alternatives.)

Target decision: [remove allergy label / confirm safe alternative / confirm reaction reproducibility]

(If indication is unclear or not documented, explicitly state this rather than inferring.)

Index Reaction History

(If no prior reaction history exists, state "No prior reaction to this drug or class documented" and omit the list below.)

• Suspected culprit drug, route, approximate dose: [Drug; route; ~dose] (Record "Unknown" for any element not available.)
• Timing from dose to symptoms: [immediate (≤1–2 hours) / delayed (>2 hours) / unknown]
• Symptoms and objective signs: [Patient descriptors and clinician-documented signs] (Use direct quotes for subjective descriptors that may be clinically important.)
• Severity markers: [ED visit / epinephrine use / hospitalization / airway involvement / skin findings / hemodynamic compromise / none / unknown]
• Treatments and response: [Therapies given; response; time to resolution]
• Time since reaction and subsequent exposures: [Interval since event; any re-exposures and outcomes]

Pre-Challenge Safety Screening

• History of severe cutaneous adverse reactions (SJS/TEN, DRESS, AGEP) to this or cross-reactive drugs: [Yes / No / Not applicable] — [Comments]
• Prior severe organ-specific reactions (hepatitis, nephritis, cytopenias): [Yes / No / Not applicable] — [Comments]
• Pregnancy or breastfeeding status: [Yes / No / Not applicable] — [Comments]
• Uncontrolled asthma, severe COPD, or unstable cardiovascular disease: [Yes / No] — [Comments]
• Beta-blocker use: [Yes / No] — [Mitigation plan if applicable]
• ACE inhibitor use: [Yes / No] — [Mitigation plan if applicable]
• Mast cell disorder history: [Yes / No] — [Comments]
• Intercurrent illness that may confound interpretation: [Yes / No] — [Comments]
• Medications that may mask reactions:
  • Antihistamines: [Held / Not held / Not applicable] — [Rationale]
  • Systemic corticosteroids: [Held / Not held / Not applicable] — [Rationale]

Baseline Assessment

• Vital signs: [Time] — HR [value]; BP [value]; RR [value]; SpO2 [value]; Temp [value]
• Focused exam:
  • Skin: [Baseline rash or hives present / absent; description if present]
  • Oropharynx: [Findings]
  • Lungs: [Findings]
  • Cardiovascular: [Findings]
• Baseline symptoms today that could be misattributed to a reaction: [Symptoms or "None"]

Consent

(Document that purpose and alternatives were discussed including avoidance, alternative drugs, skin testing, and desensitization if indicated; material risks from mild reactions through anaphylaxis and delayed rash; criteria for positive reaction and stop criteria; and that consent was obtained.)

• Consent type: [Written / Verbal per local policy]
• Interpreter: [Not required / Language and interpreter ID or method]

Challenge Protocol

(Document planned protocol before dosing begins.)

• Drug/Route/Formulation: [Drug; route; formulation; concentration]
• Target therapeutic dose: [Dose in mg or mL]
• Number of steps: [1-step / 2-step / multi-step]
• Planned dose sequence: [Percentages and actual doses for each step]
• Interval between steps: [Minutes]
• Post-final-dose observation period: [Minutes]
• Criteria to hold/abort and define pass/fail/inconclusive: [Operational criteria]
• IV access: [Placed / Not placed] — [Rationale]
• Premedications: [None / Medication, dose, route, timing] — [Rationale]
• Protocol deviations from standard practice: [None / Description and reason]

Dose Administration Log

(Add one row per step. For steps without symptoms, document "No symptoms reported; no objective changes observed.")

Step	Time Given	Dose (mg/mL)	Cumulative Dose	Vital Signs	Patient-Reported Symptoms	Objective Findings	Clinical Decision
[1]	[HH:MM]	[Dose]	[Cumulative dose]	[HR/BP/RR/SpO2]	[Quoted symptom or "No symptoms reported"]	[Findings or "No objective changes"]	[Proceed / Hold / Stop — Rationale]
[2]	[HH:MM]	[Dose]	[Cumulative dose]	[HR/BP/RR/SpO2]	[Quoted symptom or "No symptoms reported"]	[Findings or "No objective changes"]	[Proceed / Hold / Stop — Rationale]
[3]	[HH:MM]	[Dose]	[Cumulative dose]	[HR/BP/RR/SpO2]	[Quoted symptom or "No symptoms reported"]	[Findings or "No objective changes"]	[Proceed / Hold / Stop — Rationale]
(Add rows as needed)

(If vital signs are documented in a separate flowsheet, include baseline and post-final-dose vitals with flowsheet reference.)

(If no symptoms occurred requiring additional assessment, medication, delay, or termination, include the following statement:)

No adverse reaction observed; no rescue medications required.

Adverse Reaction Details

(Include this section only if symptoms occurred that triggered additional assessment, medication, delay, or termination. Otherwise omit entirely.)

• Onset time: [Time from last dose; time from challenge start]
• Systems involved and objective findings: [Skin; respiratory; cardiovascular; gastrointestinal; other]
• Anaphylaxis criteria met: [Yes / No] — [Reasoning]
• Interventions: [Medication name, dose, route, time, response] (List each intervention.)
• Non-pharmacologic actions: [Positioning; oxygen; IV fluids; monitoring; other]
• Escalation: [Rapid response / Transfer — details / None]
• Resolution time and residual symptoms: [Time to resolution; any residual effects]

Outcome / Interpretation

Result: [Pass (tolerated) / Fail (hypersensitivity reaction) / Inconclusive]

• (For Pass:) Maximum dose tolerated: [Dose]; Observation end time: [Time]
• (For Fail:) Reaction phenotype and severity: [Description]; Mechanism timing: [Immediate / Non-immediate]
• (For Inconclusive:) Reason: [Confounding symptoms / Early termination / Protocol deviation / Patient request / Other]

[Interpretation connecting result to original clinical question] (Note that a single-day challenge supports tolerance under these conditions but does not exclude all future risk or delayed reactions unless specifically assessed.)

Allergy Record Update

Before: [Existing allergy entries relevant to the challenged drug/class]

After: [Removed / Modified / Added / No change] — [Allergen name (generic; include class)] — [Reaction details if failed; tolerance statement if passed]

Date and evidence type: Observed drug challenge on [date]

Cross-reactivity guidance: [Guidance if relevant / Not applicable]

(For Pass:) Patient guidance: [Patient may take this medication as prescribed; monitor for delayed reactions; seek care if symptoms develop; inform all providers and pharmacy of updated allergy status.]

(For Fail:) Patient guidance: [Allergy retained/added with accurate reaction details; avoidance guidance; safe alternatives; whether desensitization may be appropriate for future need.]

(If allergy list cannot be updated at time of documentation, state "Allergy list update pending" and assign responsibility.)

Disposition / Follow-Up

• Observation completed: [Time]; Condition at discharge: [Stable / Other]
• Delayed reaction counseling provided: [Yes / No] — [Symptoms to watch for; when and how to seek care]
• Medications provided/prescribed: [None / Details including epinephrine autoinjector if indicated]
• Follow-up plan: [Allergy clinic PRN or scheduled; communication to referring clinician]

Clinician Attestation

I personally supervised and/or performed the graded drug challenge described above. Complications: [None / Details].

[Clinician name, credentials] — [Date/Time]